Clinical operations and patient safety
Madrigal Rezdiffra Lawsuit: Safety Allegations, Company Response and Trial Oversight
Review the disputed Madrigal Rezdiffra safety allegations, the company’s response, FDA labeling and implications for clinical trial safety oversight.
By Lampgen Clinical Research

4 min read · estimated
What the source reported
A former Madrigal Pharmaceuticals clinical-development leader has brought a whistleblower-retaliation lawsuit involving concerns about Rezdiffra (resmetirom), the company’s MASH treatment. STAT reported on November 4, 2026, that Michael Charlton, M.D., who served as senior vice president and head of clinical development from October 2024 to January 2026, alleges he was forced to resign after raising safety concerns. The claims remain disputed.
Madrigal’s Form 10-Q filed November 3 confirms that the complaint was filed October 9 in the Northern District of Illinois. The company describes allegations of retaliation following internal concerns about data and reporting practices. It disputes the allegations and says it intends to defend itself vigorously. Separately, Madrigal told Fierce Pharma that it stands behind Rezdiffra’s safety and effectiveness.
Fierce’s reporting describes allegations concerning the handling of liver-related adverse events, changes to investigator narratives before independent review, access to treatment assignments and reproducibility of conference data. These details are attributed to reporting on Charlton’s complaint. They have not been established here as findings of misconduct. We have not independently reviewed the full complaint or the underlying clinical records.
The approved treatment population is important. The July 2026 FDA prescribing information covers adults with noncirrhotic MASH and moderate to advanced fibrosis, consistent with stages F2–F3, alongside diet and exercise. The indication received accelerated approval based on improvements in MASH and fibrosis, with confirmatory clinical benefit still required. Findings from investigational cirrhosis cohorts should be distinguished from that approved population.
The existing label includes warnings for hepatotoxicity and gallbladder-related adverse reactions, as well as precautions and dose limits involving certain statins. These are documented labeling considerations. Their presence does not resolve the allegations about how additional concerns or study data were handled.
Spontaneous adverse-event reports also need careful interpretation. FDA explains that reports alone cannot establish that a medicine caused an event or determine its incidence. Duplicate reports, incomplete information, underlying illness and other treatments can affect interpretation. The public database alone cannot settle a comparative safety claim. This analysis reflects the sources available on November 4, 2026; it does not establish a court ruling or a new FDA safety determination.
What this means for trial teams
Lampgen’s interpretation is that the immediate operational question is whether a safety concern can move from a site observation to qualified review with its supporting evidence intact. The lawsuit merits careful attention while the allegations and the company’s response are evaluated. Reliable safety governance helps protect both patients and the credibility of development decisions.
For sponsors and CROs, a useful review starts with traceability. Preserve original investigator assessments, record who changes a narrative and why, and retain a reviewable history. Reconcile relevant source records, clinical databases and safety systems so that inconsistent dates, seriousness criteria, interventions and outcomes reach the appropriate team. These are proposed practices for trial teams generally, rather than findings that Madrigal failed to perform them.
Independent review also needs defined information boundaries. Trial governance should specify access to treatment assignments, management of potential conflicts and how questions reach medical reviewers or adjudication committees. Each unresolved concern should have an accountable owner, a deadline and an escalation route when the initial reviewer cannot resolve it.
CRAs support this system by recognizing discrepancies, documenting follow-up and using the study’s reporting and escalation procedures. They should have the experience and time to explain a concern clearly and confirm that the appropriate team has received it. Medical causality assessment and treatment decisions remain with qualified investigators and medical teams. Staffing plans should account for this work alongside visit volume and enrollment targets.
The cultural requirement is equally practical: staff need to be able to question an interpretation without retaliation, and leaders need a documented process for considering the challenge. An organization can support scientific disagreement while evaluating every claim fairly. Closing an action item should reflect a reasoned resolution or a clearly documented continuing question.
For patients, the potential impact is greater scrutiny of how benefit–risk evidence is generated, reviewed and communicated. A lawsuit alone does not establish a medicine’s safety profile or justify a treatment change. Patients with questions should discuss their own treatment and monitoring with their prescribing clinician. For development teams, stronger documentation and responsive review can help preserve confidence in the evidence.
Lampgen specializes in oncology CRA staffing and clinical-operations resourcing. The relevance to oncology is the shared need for accurate safety timelines, sound investigator documentation and timely escalation in complex studies. Our perspective is that staffing for judgment and follow-through matters alongside the number of monitoring visits completed.